SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd Stock
Equities
688336
CNE1000062X2
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 23.96 CNY | +1.91% |
|
+8.71% | +6.44% |
| Apr. 25 | Sunshine Guojian Pharmaceutical Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Mar. 21 | Sunshine Guojian Pharmaceutical's Profit Surges Sixfold in 2023 | MT |
| Sales 2024 * | 1.2B 166M | Sales 2025 * | 1.33B 184M | Capitalization | 14.78B 2.04B |
|---|---|---|---|---|---|
| Net income 2024 * | 207M 28.59M | Net income 2025 * | 233M 32.18M | EV / Sales 2024 * | 12.3 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 11.1 x |
| P/E ratio 2024 * |
70.5
x | P/E ratio 2025 * |
63.1
x | Employees | 965 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 13.16% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.91% | ||
| 1 week | +8.71% | ||
| Current month | +4.77% | ||
| 1 month | +4.77% | ||
| 3 months | +14.31% | ||
| 6 months | +8.17% | ||
| Current year | +6.44% |
1 week
20.91
24.51
1 month
20.5824.51
Current year
16.1526.78
1 year
16.0226.78
3 years
11.9526.78
5 years
11.9557.52
10 years
11.9557.52
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-30 | 23.96 | +1.91% | 3,344,841 |
| 24-04-29 | 23.51 | -.--% | 3,982,842 |
| 24-04-26 | 23.51 | +8.09% | 6,263,315 |
| 24-04-25 | 21.75 | +1.16% | 4,946,040 |
| 24-04-24 | 21.5 | -5.78% | 4,352,591 |
End-of-day quote Shanghai S.E., April 29, 2024
More quotes
Sunshine Guojian Pharmaceutical Shanghai Co Ltd is a China-based company mainly engaged in the research and development, industrialization and commercialization of antibody drugs. Its products are mainly used to treat major diseases such as autoimmune diseases and tumors. The Companyâs product, recombinant human type II tumor necrosis factor receptor-antibody fusion protein (trade name: YISAIPU), is a fully human antibody drug used to treat rheumatoid arthritis, ankylosing spondylitis and psoriasis. The Company mainly conducts its businesses in Mainland China.
Sector
Pharmaceuticals
Calendar
2024-08-21
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
23.96
CNY
Average target price
32.43
CNY
Spread / Average Target
+35.35%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +6.44% | 2.04B | |
| -4.24% | 86.85B | |
| +2.76% | 40.16B | |
| -16.72% | 31.28B | |
| +57.86% | 25.27B | |
| -14.71% | 15.33B | |
| -9.12% | 11.96B | |
| -42.56% | 11.61B | |
| +6.89% | 8.83B | |
| -10.53% | 7.94B |
- Stock Market
- Equities
- 688336 Stock
